Davis Polk advised the representatives of the initial purchasers on Rule 144A/Regulation S offerings by Mylan N.V. (“Mylan”) of $1.0 billion aggregate principal amount of its 2.500% senior notes due 2019, $2.25 billion aggregate principal amount of its 3.150% senior notes due 2021, $2.25 billion aggregate principal amount of its 3.950% senior notes due 2026 and $1.0 billion aggregate principal amount of its 5.250% senior notes due 2046. Mylan intends to use a portion of the net proceeds from the offerings to finance its proposed acquisition of Meda AB (publ) (“Meda”).

Mylan is a global pharmaceutical company committed to setting new standards in health care. Mylan offers a growing portfolio of around 1,400 generic and branded pharmaceuticals and several brand medications. In addition, Mylan offers a wide range of antiretroviral therapies on which nearly 50% of people being treated for HIV/AIDS in the developing world depend. Mylan also operates one of the largest active pharmaceutical ingredient manufacturers and currently markets products in about 165 countries and territories.

Meda, based in Sweden, is a leading international specialty pharma company with a broad product portfolio reaching more than 80% of the global pharmaceutical market. Measured by sales, Meda is the 48th largest pharmaceutical company in the world.

The Davis Polk capital markets team included partner John B. Meade and associates Yasin Keshvargar, Donald Shum, Win Rutherfurd and Nara Lee. The U.S. tax team included counsel Alon Gurfinkel and associate Vinay Prabhakar. The U.K. tax team included partner Jonathan Cooklin and associate Dominic Foulkes. Members of the Davis Polk team are based in the New York and London offices.

Copy link to share post